SCHEMBL4242010

SCHEMBL4242010

O=C(O)Nc1ccccc1Cc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.56
IDH1 O75874 1/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 2/20 0.48
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44
SUCNR1 Q9BXA5 3/20 0.44
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172605 0.88 L3MBTL1 (0.70) L3MBTL1IDH1MEN1KMT2ALMNA
SCHEMBL27547012 0.86 L3MBTL1 (0.68) L3MBTL1IDH1MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL11164652 0.86 L3MBTL1 (0.68) L3MBTL1IDH1MEN1KMT2ALMNA
SCHEMBL4237601 0.85 L3MBTL1 (0.62) L3MBTL1MEN1KMT2ALMNANPC1
SCHEMBL4621396 0.85 L3MBTL1 (0.58) L3MBTL1IDH1MEN1KMT2ALMNA
SCHEMBL10691682 0.84 NPC1 (0.53) L3MBTL1IDH1MEN1KMT2ALMNA
SCHEMBL4237309 0.84 L3MBTL1 (0.56) L3MBTL1MEN1KMT2ALMNANPC1
SCHEMBL4622869 0.82 L3MBTL1 (0.56) L3MBTL1MEN1KMT2ALMNAMAPT
SCHEMBL6830332 0.80 L3MBTL1 (0.49) L3MBTL1MEN1KMT2ANPC1RAB9A
SCHEMBL4681910 0.80 ALDH1A1 (0.62) L3MBTL1MEN1KMT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US claimed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP claimed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO claimed
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US disclosed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP disclosed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012116-A1 Muscarinic Receptor Antagonists CHRM3, CHRM2, CHRM5 L3MBTL1 4211/4885IDH1 4651/4885MEN1 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.